Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
Shunji Takahashi(Japanese Foundation For Cancer Research), Noboru Yamamoto(Tokyo National Hospital), Tomonari Yamashita(Daiichi-Sankyo (Japan)), Takafumi Koyama(Tokyo National Hospital), Toshio Shimizu(Wakayama Medical University), Kenji Nakano(National Center for Global Health and Medicine), Sakura Sakajiri(Juntendo University Urayasu Hospital), Yutaka Fujiwara(Aichi Cancer Center), Mariko Ogura(The Cancer Institute Hospital), Yasuyuki Kakurai(Daiichi-Sankyo (Japan)), Masaya Tachibana(Daiichi-Sankyo (Japan)), Junichi Tomomatsu(The Cancer Institute Hospital)
Cited by 72
Related Papers
E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432